Advertisement

Allergo Journal International

, Volume 28, Issue 4, pp 99–102 | Cite as

Omalizumab as a last resort therapy for intractable, severe chronic allergic rhinosinusitis

  • Ciro RomanoEmail author
  • Gianvito Pace
  • Ausilia Sellitto
  • Alfonso Reginelli
case report
  • 22 Downloads

Background

Allergic rhinitis (AR) is a highly prevalent condition affecting 10 to 40% of the general population. Symptomatic AR has a negative impact on daily activities and may result in absenteeism or reduced productivity and performance at work. Although therapy for AR is well codified, there still remains a considerable proportion of patients who fail to respond to standard therapy and remain a challenge in every day clinical practice.

Omalizumab, a humanized anti-IgE monoclonal antibody, is currently licensed for moderate to severe allergic asthma and chronic urticaria. Because of its mechanism(s) of action, omalizumab may theoretically be useful in several IgE-mediated diseases in case of poor control with standard therapy. Indeed, a number of case reports or small case series can be retrieved from the medical literature with regard to further potential uses of omalizumab in diseases other than allergic asthma and chronic urticaria where IgE may be supposed to play a pathogenic...

Keywords

Allergic rhinitis Sinusitis Omalizumab Off-label Treatment 

Notes

Conflict of interest

C. Romano, G. Pace, A. Sellitto and A. Reginelli declare that they have no competing interests.

References

  1. 1.
    Romano C, Sellitto A, De Fanis U, Balestrieri A, Savoia A, Abbadessa S, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 2015;35:159–68.CrossRefGoogle Scholar
  2. 2.
    Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy. 2018;73:230–8.CrossRefGoogle Scholar
  3. 3.
    Romano C, Sellitto A, De Fanis U, Esposito G, Arbo P, Giunta R, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104:95–7.CrossRefGoogle Scholar
  4. 4.
    Masieri S, Cavaliere C, Begvarfaj E, Rosati D, Minni A. Effects of omalizumab therapy on allergic rhinitis: a pilot study. Eur Rev Med Pharmacol Sci. 2016;20:5249–55.PubMedGoogle Scholar
  5. 5.
    Clavenna MJ, Turner JH, Samuelson M, Tanner SB, Duncavage J, Chandra RK. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis. Allergy Asthma Proc. 2016;37:23–6.CrossRefGoogle Scholar
  6. 6.
    Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–40:e1.Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, a part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Internal Medicine, Department of Medical and Surgical Sciences“Luigi Vanvitelli” University School of MedicineNaplesItaly
  2. 2.Radiology Unit, Department of Precision Medicine“Luigi Vanvitelli” University School of MedicineNaplesItaly
  3. 3.“S. Giuseppe Moscati” HospitalAvellinoItaly

Personalised recommendations